Cancer Moonshot Grant Awarded for Development of Riptide Drug Candidates
August 3, 2023
WASHINGTON, DC. – The White House has announced that Dr. Jelani Zarif of the Johns Hopkins School of Medicine has received a Cancer Moonshot Scholars R01 grant from the National Institutes of Health / National Cancer Institute (NIH/NCI), for his continuing research using Riptide peptide drug candidates to address metastatic prostate cancer. Dr. Zarif becomes one of just eleven grant recipients in the initial cohort of Cancer Moonshot Scholars, representing the most promising research approaches to oncology indications.
Targeted Peptides Show Promise for PET Imaging of Tumor-Associated Macrophages
March 23, 2023
TUSKEGEE, AL. – A joint development effort by Riptide Bioscience, Inc., and scientists from the Radiochemistry Laboratory of the Heersink School of Medicine, University of Alabama, have shown that radiolabeled peptides designed by Riptide, specifically identify concentrations of tumor-associated macrophages (TAMs) in a murine cancer model.
CD206 Targeting Peptide Retards Induced Fibrosis in Murine Models
March 18, 2023
SAN FRANCISCO, CA. – Researchers at Riptide Bioscience, Inc., working with physician/scientists at the College of Medicine, University College London, have reported inhibition of pulmonary fibrosis in a murine model through intratracheal administration of CD206-targeting peptides. This work is the subject of a peer-reviewed article published in the current issue of Cells.
< Additional articles > Next page